The medically insured persons who suffer from hypertension will have access to one more compensated medicine with the international common name Nebivololum as from April 1. The medicine that is used to treat cardiovascular diseases will be prescribed not only to patients with cardiac insufficiency, but also to those with hypertension, regardless of age, according to medical indications, IPN reports.

The Ministry of Health said the drug will be compensated in proportion of 80% of the median sales price of two commercial names present on the market. About 70,000 persons will receive the compensated Nebivololum each year. The annual reimbursed average cost per patient is 657 lei. The National Health Insurance Company estimated that 46 million lei is needed annually to compensate the given medicine. The money was earmarked in the mandatory health insurance funds.

Also, the insured patients with cardiovascular diseases, atrial fibrillation with increased risk of a stroke and other related diseases and those who will undergo knee and hip surgery will benefit from the compensated drug Rivaroxabanum. All the five commercial names of this medicine will be fully compensated for children under 18. Rivaroxaban-BP and Rovaltro will be fully compensated for adults, while the rest will be only partially compensated. The about 28.8 million lei needed for the purpose will be allocated from the mandatory health insurance funds.